Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:AVXL NASDAQ:ELTX NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.23-0.4%$2.47$2.03▼$4.00$227.97M1.57240,254 shs384,396 shsAVXLAnavex Life Sciences$2.40-3.2%$2.62$2.26▼$12.81$229.83M1.141.06 million shs1.01 million shsELTXElicio Therapeutics$3.00-4.8%$6.84$2.66▼$16.00$57.26M1.261.14 million shs247,244 shsSGMTSagimet Biosciences$7.07+0.9%$7.09$4.50▼$11.41$228.42M3.351.35 million shs910,905 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-0.45%+1.36%-12.20%-21.48%-4.70%AVXLAnavex Life Sciences-3.23%+0.42%-6.25%-28.14%-82.10%ELTXElicio Therapeutics-4.76%-3.54%-24.62%-74.34%-67.81%SGMTSagimet Biosciences+0.86%-9.59%+2.02%+20.65%-26.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.23-0.4%$2.47$2.03▼$4.00$227.97M1.57240,254 shs384,396 shsAVXLAnavex Life Sciences$2.40-3.2%$2.62$2.26▼$12.81$229.83M1.141.06 million shs1.01 million shsELTXElicio Therapeutics$3.00-4.8%$6.84$2.66▼$16.00$57.26M1.261.14 million shs247,244 shsSGMTSagimet Biosciences$7.07+0.9%$7.09$4.50▼$11.41$228.42M3.351.35 million shs910,905 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-0.45%+1.36%-12.20%-21.48%-4.70%AVXLAnavex Life Sciences-3.23%+0.42%-6.25%-28.14%-82.10%ELTXElicio Therapeutics-4.76%-3.54%-24.62%-74.34%-67.81%SGMTSagimet Biosciences+0.86%-9.59%+2.02%+20.65%-26.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.40Hold$7.50236.32% UpsideAVXLAnavex Life Sciences 2.40Hold$21.33788.89% UpsideELTXElicio Therapeutics 2.50Moderate Buy$19.75558.33% UpsideSGMTSagimet Biosciences 2.64Moderate Buy$25.57261.69% UpsideCurrent Analyst Ratings BreakdownLatest ELTX, AVXL, ACIU, and SGMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026SGMTSagimet Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026ELTXElicio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/1/2026ACIUAC Immune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026ELTXElicio Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/16/2026ELTXElicio Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/15/2026ELTXElicio Therapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026ELTXElicio Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $23.006/11/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/10/2026ELTXElicio Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.005/28/2026ELTXElicio Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/27/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$4.31M52.66N/AN/A$0.54 per share4.13AVXLAnavex Life SciencesN/AN/AN/AN/A$1.10 per shareN/AELTXElicio TherapeuticsN/AN/AN/AN/A$0.09 per shareN/ASGMTSagimet BiosciencesN/AN/AN/AN/A$3.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$85.03M-$0.82N/A13.12N/A-1,788.02%-125.26%-40.85%8/4/2026 (Estimated)AVXLAnavex Life Sciences-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%7/30/2026 (Estimated)ELTXElicio Therapeutics-$39.57M-$2.40N/AN/AN/AN/A-2,748.16%-151.12%8/6/2026 (Estimated)SGMTSagimet Biosciences-$51.04M-$1.34N/AN/AN/AN/A-37.57%-35.52%8/12/2026 (Estimated)Latest ELTX, AVXL, ACIU, and SGMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026SGMTSagimet Biosciences-$0.28N/AN/AN/AN/AN/A8/11/2026Q2 2026AVXLAnavex Life Sciences-$0.08N/AN/AN/AN/AN/A8/6/2026Q2 2026ELTXElicio Therapeutics-$0.53N/AN/AN/AN/AN/A8/4/2026Q2 2026ACIUAC Immune$0.0981N/AN/AN/A$34.08 millionN/A7/30/2026Q2 2026AVXLAnavex Life Sciences-$0.07N/AN/AN/AN/AN/A5/12/2026Q1 2026SGMTSagimet Biosciences-$0.39-$0.33+$0.06-$0.33N/AN/A5/11/2026Q1 2026ELTXElicio Therapeutics-$0.49-$0.65-$0.16-$0.65N/AN/A4/30/2026Q1 2026ACIUAC Immune-$0.20-$0.19+$0.01-$0.19$0.33 million$1.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/AELTXElicio TherapeuticsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC Immune0.110.871.02AVXLAnavex Life SciencesN/A20.8720.87ELTXElicio Therapeutics5.752.242.24SGMTSagimet BiosciencesN/A20.3320.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%AVXLAnavex Life Sciences31.55%ELTXElicio Therapeutics35.03%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%AVXLAnavex Life Sciences11.40%ELTXElicio Therapeutics50.90%SGMTSagimet Biosciences11.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140101.77 million97.09 millionOptionableAVXLAnavex Life Sciences4092.67 million82.11 millionOptionableELTXElicio TherapeuticsN/A19.09 million9.37 millionNot OptionableSGMTSagimet Biosciences832.59 million28.84 millionOptionableELTX, AVXL, ACIU, and SGMT HeadlinesRecent News About These CompaniesAffinity Asset Advisors LLC Decreases Position in Sagimet Biosciences Inc. $SGMTJuly 25 at 3:12 AM | marketbeat.comSagimet Biosciences (SGMT) Attracts Attention After Russel Indexes InclusionJuly 15, 2026 | insidermonkey.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 12, 2026 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Stock Price Down 1.2% - Here's What HappenedJuly 10, 2026 | marketbeat.comSagimet Biosciences Joins the Russell 2000® and Russell 3000® IndexesJune 29, 2026 | globenewswire.comSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 22, 2026 | globenewswire.comSagimet Biosciences Announces Board Changes and Director ElectionsJune 12, 2026 | tipranks.comHere's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom FisherJune 4, 2026 | zacks.comSagimet Biosciences Grants New Performance-Based Executive Equity AwardsJune 3, 2026 | tipranks.comSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASHMay 27, 2026 | globenewswire.comSagimet Biosciences Inc - Ordinary Shares - Series AMay 21, 2026 | money.usnews.comWall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to TradeMay 21, 2026 | zacks.comSagimet Biosciences (SGMT) price target increased by 15.00% to 29.86May 15, 2026 | msn.comSagimet Biosciences: Making The Bull Case For Differentiated DenifanstatMay 14, 2026 | seekingalpha.comSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 13, 2026 | globenewswire.comSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 12, 2026 | globenewswire.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from JonesTradingMay 11, 2026 | theglobeandmail.comSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in ChicagoMay 11, 2026 | globenewswire.comSagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?May 5, 2026 | zacks.comDoes Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?May 5, 2026 | zacks.comSagimet Biosciences stock surges 30% on acne trial plansApril 28, 2026 | au.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELTX, AVXL, ACIU, and SGMT Company DescriptionsAC Immune NASDAQ:ACIU$2.23 -0.01 (-0.45%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.22 -0.01 (-0.45%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Anavex Life Sciences NASDAQ:AVXL$2.40 -0.08 (-3.23%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.40 +0.00 (+0.17%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Elicio Therapeutics NASDAQ:ELTX$3.00 -0.15 (-4.76%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.08 +0.09 (+2.83%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.Sagimet Biosciences NASDAQ:SGMT$7.07 +0.06 (+0.86%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$7.06 -0.01 (-0.14%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
